Patents by Inventor Noriyuki Kamei

Noriyuki Kamei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for producing (R)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione and intermediate for producing same
    Patent number: 10640484
    Abstract: A method for producing (R)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione, the method comprising, (a) a step for isolating an isomer represented by formula (2) from a mixture of isomers represented by formula (1), and (b) a step for obtaining (R)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione by removing the menthyloxycarbonyl group from the compound represented by formula (2), which was isolated in step (a).
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: May 5, 2020
    Assignee: KAKEN PHARMACEUTICAL CO., LTD.
    Inventors: Yoshitake Sumikawa, Noriyuki Kamei, Shingo Todo
  • METHOD FOR PRODUCING (R)-5-(3,4-DIFLUOROPHENYL)-5-[(3-METHYL-2-OXOPYRIDIN-1(2H)-YL)METHYL]IMIDAZOLIDINE-2,4-DIONE AND INTERMEDIATE FOR PRODUCING SAME
    Publication number: 20190276428
    Abstract: A method for producing (R)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione, the method comprising, (a) a step for isolating an isomer represented by formula (2) from a mixture of isomers represented by formula (1), and (b) a step for obtaining (R)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione by removing the menthyloxycarbonyl group from the compound represented by formula (2), which was isolated in step (a).
    Type: Application
    Filed: September 21, 2017
    Publication date: September 12, 2019
    Applicant: KAKEN PHARMACEUTICAL CO., LTD.
    Inventors: Yoshitake SUMIKAWA, Noriyuki KAMEI, Shingo TODO
  • Pyridone derivative, pharmaceutical containing the same and methods of use thereof
    Patent number: 10000476
    Abstract: General formula (I): The present invention pertains to: a pyridone derivate or a salt thereof represented by general formula (I); or a medicine containing the pyridone derivative or salt thereof as an active ingredient. [In the formula, ring A, R1, R2, R3 and R4 are specific groups.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: June 19, 2018
    Assignee: KAKEN PHARMACEUTICAL CO., LTD.
    Inventors: Noriyuki Kamei, Yoshitake Sumikawa, Daigo Kamimura, Shingo Todo, Takuya Yamada, Shota Tokuoka
  • (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione and drug containing same
    Patent number: 9518041
    Abstract: Provided is (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof. Also provided is a drug containing as the active ingredient (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: December 13, 2016
    Assignee: KAKEN PHARMACEUTICAL CO., LTD.
    Inventors: Noriyuki Kamei, Daigo Kamimura, Yoshitake Sumikawa, Shota Tokuoka
  • PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME
    Publication number: 20160340349
    Abstract: General formula (I): The present invention pertains to: a pyridone derivate or a salt thereof represented by general formula (I); or a medicine containing the pyridone derivative or salt thereof as an active ingredient. [In the formula, ring A, R1, R2, R3 and R4 are specific groups.
    Type: Application
    Filed: August 9, 2016
    Publication date: November 24, 2016
    Applicant: KAKEN PHARMACEUTICAL CO., LTD.
    Inventors: Noriyuki KAMEI, Yoshitake SUMIKAWA, Daigo KAMIMURA, Shingo TODO, Takuya YAMADA, Shota TOKUOKA
  • Pyridone derivative and pharmaceutical containing same
    Patent number: 9447072
    Abstract: General formula (I): The present invention pertains to: a pyridone derivate or a salt thereof represented by general formula (I); or a medicine containing the pyridone derivative or salt thereof as an active ingredient. [In the formula, ring A, R1, R2, R3 and R4 are specific groups.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: September 20, 2016
    Assignee: KAKEN PHARMACEUTICAL CO., LTD.
    Inventors: Noriyuki Kamei, Yoshitake Sumikawa, Daigo Kamimura, Shingo Todo, Takuya Yamada, Shota Tokuoka
  • (+)-5-(3,4-DIFLUOROPHENYL)-5-[(3-METHYL-2-OXOPYRIDIN-1(2H)- YL)METHYL]IMIDAZOLIDINE-2,4-DIONE AND DRUG CONTAINING SAME
    Publication number: 20160130248
    Abstract: Provided is (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof. Also provided is a drug containing as the active ingredient (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof.
    Type: Application
    Filed: June 6, 2014
    Publication date: May 12, 2016
    Applicant: KAKEN PHARMACEUTICAL CO., LTD.
    Inventors: Noriyuki KAMEI, Daigo KAMIMURA, Yoshitake SUMIKAWA, Shota TOKUOKA
  • PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME
    Publication number: 20150166506
    Abstract: General formula (I): The present invention pertains to: a pyridone derivate or a salt thereof represented by general formula (I); or a medicine containing the pyridone derivative or salt thereof as an active ingredient. [In the formula, ring A, R1, R2, R3 and R4 are specific groups.
    Type: Application
    Filed: December 7, 2012
    Publication date: June 18, 2015
    Applicant: KAKEN PHARMACEUTICAL CO., LTD.
    Inventors: Noriyuki Kamei, Yoshitake Sumikawa, Daigo Kamimura, Shingo Todo, Takuya Yamada, Shota Tokuoka
  • Reverse hydroxamic acid derivatives
    Patent number: 7511144
    Abstract: Reverse hydroxamic acid derivatives having specific structure represented by a general formula (Ia): (wherein A is a hydrogen atom or the like; Ar1 is an arylene or the like; Ar2 is an optionally substituted aryl, a heteroaryl or the like; R1 is a hydrogen atom, an alkyl or the like; R2a is a substituted cycloaryl, a heterocycloaryl or the like) and a general formula (I): (wherein A, Ar1, Ar2, and R1 are the same as defined above and R2 is an hydrogen atom, R2a or the like) and salts thereof, which have TNF-? converting enzyme (TACE) inhibitory activity.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: March 31, 2009
    Assignee: Kaken Pharmaceutical Co., Ltd.
    Inventors: Masanao Shimano, Noriyuki Kamei, Tomohiro Tanaka, Tatsuhiro Harada, Makoto Haino, Akihiko Okuyama, Yoshio Arakawa, Yoshiko Murakami
  • Reverse hydroxamic acid derivatives
    Publication number: 20040242928
    Abstract: Reverse hydroxamic acid derivatives having specific structure represented by a general formula (Ia): 1
    Type: Application
    Filed: March 4, 2004
    Publication date: December 2, 2004
    Inventors: Masanao Shimano, Noriyuki Kamei, Tomohiro Tanaka, Tatsuhiro Harada, Makoto Haino, Akihiko Okuyama, Yoshio Arakawa, Yoshiko Murakami